Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration

Documenti analoghi

• Disclosure of plasma p‐tau217 measure improves diagnostic confidence in patients with Alzheimer's disease versus syndromes associated with frontotemporal lobar degeneration
  di: Valentina Cantoni, et al.
  Pubblicazione: (2025)
• Predicting survival rate by plasma biomarkers and clinical variables in syndromes associated with frontotemporal lobar degeneration
  di: Maria Sofia Cotelli, et al.
  Pubblicazione: (2025)
• A protein panel including pTau217 outperforms pTau217 alone in identifying high tau load in amyloid positive individuals
  di: Guglielmo Di Molfetta, et al.
  Pubblicazione: (2025)
• Alpha tACS Improves Cognition and Modulates Neurotransmission in Dementia with Lewy Bodies
  di: Alberto Benussi, et al.
  Pubblicazione: (2024)
• Neurodegeneration and acute neuronal injury drastically skew the p‐tau217/non‐p217 ratio in both CSF and plasma regardless of analytical technique – a mass spectrometry and Simoa study
  di: Kaj Blennow
  Pubblicazione: (2024)